Lilian Van Wagensveld

Maastricht, LI 6229HX, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Journal: Research square

Published: November 19, 2025

Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes.

Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes.

Journal: Cancer discovery

Published: August 27, 2025

Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes.

Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes.

Journal: Cancer discovery

Published: August 27, 2025

The prognostic value of tumor-stroma ratio and a newly developed computer-aided quantitative analysis of routine H&E slides in high-grade serous ovarian cancer.

The prognostic value of tumor-stroma ratio and a newly developed computer-aided quantitative analysis of routine H&E slides in high-grade serous ovarian cancer.

Journal: Research square

Published: November 28, 2023

High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer.

High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer.

Journal: The oncologist

Published: October 16, 2023

Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".

Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".

Journal: Journal of gynecologic oncology

Published: December 06, 2022

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.

Journal: Cancers

Published: November 02, 2022

Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.

Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.

Journal: Nature communications

Published: March 29, 2022

The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.

The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.

Journal: Cancers

Published: November 08, 2021

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.

Journal: British journal of cancer

Published: October 11, 2021

Conflicting Effects of Fetal Growth Restriction on Blood Pressure Between Human and Rat Offspring: A Meta-Analysis.

Conflicting Effects of Fetal Growth Restriction on Blood Pressure Between Human and Rat Offspring: A Meta-Analysis.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: January 28, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026